Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6331251 | 1.00 | ALDH1A1 (0.41) | ALDH1A1PKMTSHRCA1CA2 | |
| SCHEMBL6056887 | 0.97 | ALDH1A1 (0.44) | ALDH1A1PKMTSHRCA1CA2 | |
| SCHEMBL16617790 | 0.91 | CTDSP1 (0.39) | ALDH1A1PKMTSHRCA1CA2 | |
| SCHEMBL16625925 | 0.82 | TSHR (0.41) | ALDH1A1PKMTSHRHSD11B1HSD11B2 | |
| SCHEMBL6355777 | 0.80 | CA1 (0.36) | ALDH1A1PKMTSHRCA1CA2 | |
| SCHEMBL16625923 | 0.80 | TSHR (0.38) | ALDH1A1PKMTSHRCA1CA2 | |
| SCHEMBL1643437 | 0.79 | CA1 (0.39) | ALDH1A1PKMTSHRCA1CA2 | |
| SCHEMBL8254998 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRHSD11B1KDM4EAPOBEC3A | |
| SCHEMBL16625922 | 0.78 | TSHR (0.38) | TSHRHSD11B1KDM4EAPOBEC3ACTDSP1 | |
| SCHEMBL22470037 | 0.75 | ALDH1A1 (0.41) | ALDH1A1TSHRCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | ZEON CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1420005-A1 | CYCLOPENTANONE DERIVATIVE | Zeon Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | PTGIS, CYP51A1, TRPA1 | ALDH1A1 954/4885PKM 1093/4885TSHR 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.